Division of Nephrology and Hypertension, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Department of Pharmacology, University of California San Diego, La Jolla, CA, USA.
Pflugers Arch. 2020 Sep;472(9):1345-1370. doi: 10.1007/s00424-020-02361-w. Epub 2020 Mar 6.
The kidneys filter large amounts of glucose. To prevent the loss of this valuable fuel, the tubular system of the kidney, particularly the proximal tubule, has been programmed to reabsorb all filtered glucose. The machinery involves the sodium-glucose cotransporters SGLT2 and SGLT1 on the apical membrane and the facilitative glucose transporter GLUT2 on the basolateral membrane. The proximal tubule also generates new glucose, particularly in the post-absorptive phase but also to enhance bicarbonate formation and maintain acid-base balance. The glucose reabsorbed or formed by the proximal tubule is primarily taken up into peritubular capillaries and returned to the systemic circulation or provided as an energy source to further distal tubular segments that take up glucose by basolateral GLUT1. Recent studies provided insights on the coordination of renal glucose reabsorption, formation, and usage. Moreover, a better understanding of renal glucose transport in disease states is emerging. This includes the kidney in diabetes mellitus, when renal glucose retention becomes maladaptive and contributes to hyperglycemia. Furthermore, enhanced glucose reabsorption is coupled to sodium retention through the sodium-glucose cotransporter SGLT2, which induces secondary deleterious effects. As a consequence, SGLT2 inhibitors are new anti-hyperglycemic drugs that can protect the kidneys and heart from failing. Recent studies discovered unique roles for SGLT1 with implications in acute kidney injury and glucose sensing at the macula densa. This review discusses established and emerging concepts of renal glucose transport, and outlines the need for a better understanding of renal glucose handling in health and disease.
肾脏过滤大量的葡萄糖。为了防止这种有价值燃料的流失,肾脏的管状系统,特别是近端肾小管,已经被编程来重吸收所有滤过的葡萄糖。这一过程涉及到顶端膜上的钠-葡萄糖协同转运蛋白 SGLT2 和 SGLT1,以及基底外侧膜上的易化葡萄糖转运蛋白 GLUT2。近端肾小管还会产生新的葡萄糖,特别是在吸收后阶段,但也会增强碳酸氢盐的形成并维持酸碱平衡。近端肾小管重吸收或形成的葡萄糖主要被摄取到管周毛细血管中,并返回全身循环,或提供给进一步摄取葡萄糖的远端管状段,这些葡萄糖通过基底外侧 GLUT1 摄取。最近的研究提供了对肾脏葡萄糖重吸收、形成和利用的协调的深入了解。此外,对疾病状态下肾脏葡萄糖转运的理解也在不断加深。这包括糖尿病中的肾脏,此时肾脏葡萄糖保留变得适应不良,并导致高血糖。此外,通过钠-葡萄糖协同转运蛋白 SGLT2 促进了葡萄糖的重吸收与钠的保留,这会引起继发性的有害影响。因此,SGLT2 抑制剂是新的抗高血糖药物,可以保护肾脏和心脏免受衰竭。最近的研究发现 SGLT1 具有独特的作用,这对急性肾损伤和在致密斑处的葡萄糖感应有影响。这篇综述讨论了肾脏葡萄糖转运的既定和新兴概念,并概述了在健康和疾病中更好地理解肾脏葡萄糖处理的必要性。